SAN FRANCISCO, Jan 8 – Investors are expected to take a “back to basics” approach to genomics during 2001 as they seek companies that are generating revenues from fully developed technologies, Rob Olan, a life science technology analyst at JP Morgan H&Q, said Monday. 

“In general, the atmosphere is going to be less euphoric,” Olan told GenomeWeb at the start of the JP Morgan H&Q healthcare conference. “Companies that are more established will do better.” 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.